Cardiovascular Risk Factors in Rheumatoid Arthritis Patients ( Comparison Between Seronegative and Seropositive Cases )

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06738264

Enrollment

100

Registered

2024-12-17

Start date

2025-01-01

Completion date

2025-10-01

Last updated

2024-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The goal of this observational study is to learn about the long-term effects rheumatoid arthritis (RA) on cardiovascular system. The main question it aims to answer is: Does seropositive raise risk of cardiovascular diseases more than seronegative RA ?

Detailed description

We will investigate cardiovascular risk factors in patients with seronegative and seropositive rheumatoid arthritis. Complete clinical examination including blood pressure (BP; using an automatic BP monitor) and heart rate (in beats per minute (bpm) either from an automatic BP monitor or a 12 lead ECG) will be measured according to the standard hospital procedures. Routine Laboratory investigations, including complete blood count (CBC), Blood parameters, including autoantibodies and lipid profile will be determined), liver and kidney function tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and lipid profile panel will be recorded. The disease activity score-28 (DAS-28) and health assessment questionnaire (HAQ) will be assessed. Framingham risk score will be calculated. Carotid doppler will be done . Current medications use including synthetic disease-modifying anti-rheumatic drugs (DMARDs), in addition to steroids, will be recorded. Rheumatoid Factor and Anticitrullinated proteins antibodies presence will be determined. Cardiovascular risk factors, including inflammation, hypertension, smoking, obesity, and dyslipidemia will be observed and a higher risk of Cardiovascular Diseases events (including myocardial infarction, stroke, and heart failure).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Adult patients ≥ 18 years. * Both sexes. * All patients with RA confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology EULAR classification criteria * RA diagnosed for at least six months to ensure chronicity.

Exclusion criteria

* Diagnosis of other significant autoimmune diseases (e.g., lupus, scleroderma). * Use of medications known to significantly affect cardiovascular outcomes (e.g., certain anticoagulants or anti-inflammatory agents) that are not part of standard RA treatment.

Design outcomes

Primary

Measure	Time frame	Description
carotid artery wall thickness	one week	abnormality in carotid doppler

Contacts

Primary Contactamna mohamed ameen

amnaameen992@gmail.com01010283972

Outcome results